Stephen K. Burley, MD, DPhil, has been named as Co–Program Leader of the Cancer Pharmacology Research Program at Rutgers Cancer Institute of New Jersey. This basic science program unites investigators with broad scientific expertise who share a strong interest in cancer pharmacology and preclinical drug development. The aim of the program is to discover, design, and develop new anticancer agents that will translate into more effective cancer treatments. In this new role, Dr. Burley will work with Co–Program Leader X.F. ­Steven Zheng, PhD, Professor at Rutgers Robert Wood Johnson Medical School, in determining the mode of action and mechanism of resistance to anticancer agents and developing novel concepts and strategies for cancer treatment. ■